Results 171 to 180 of about 236,526 (353)

Investigating the Effects of Gossypetin on Liver Health in Diet-Induced Pre-Diabetic Male Sprague Dawley Rats

Molecules
The rising prevalence of non-alcoholic fatty liver disease among patients with type 2 diabetes mellitus has emerged as a global health challenge. Gossypetin (GTIN) is a natural flavonoid which has recently demonstrated antihyperglycaemic, antioxidant ...
Karishma Naidoo, Andile Khathi
doaj   +1 more source

Mice with hyperbilirubinemia due to Gilbert’s syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARα [PDF]

, 2017
Terry D. Hinds, Peter A. Hosick, Shujuan Chen, Robert H. Tukey, Michael W. Hankins, Andrea L. Nestor‐Kalinoski, David E. Stec   +6 more
openalex   +1 more source

Trends in the Racial and Ethnic Disparity and Predictors of Hepatic Steatosis: Data From NHANES III and NHANES 2017–2018

, 2021
Magda Shaheen, Deyu Pan, Katrina M. Schrode, Dulcie Kermah, Sonia M. Najjar, Theodore C. Friedman   +5 more
openalex   +1 more source

Dual Targeting Approach Using 4‐Hydroxytamoxifen Neuropeptide Y Conjugates for Selective Addressing of Adipose Tissue

ChemMedChem, EarlyView.
The [F7,P34]‐pNPY based peptide‐drug conjugate targets the Y1 receptor and induces internalization. Once inside the cell, 4‐hydroxytamoxifen is cleaved from the peptide and is released into the cytosol, where it activates the estrogen receptor α. This dual‐targeting mechanism aims to promote body weight loss and offers a potential therapeutic strategy ...
Anna Kohler, Eva‐Maria Jülke, Luke C. Darveniza, Jan Stichel, Annette G. Beck‐Sickinger   +4 more
wiley   +1 more source

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

Hepatology, EarlyView., 2022
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger, Holly E. Holmes, Tina Hu‐Seliger, Rodney W. Butt, Stephen A. Harrison, Dariush Mozaffarian, Oliver Chen, Leonard Guarente   +7 more
wiley   +1 more source

Genetic implications in patients with NAFLD

Journal of Education, Health and Sport
Introduction and purpose: Non-alcoholic fatty liver disease's growing prevalence and the complications it brings constitutes a serious problem nowadays.
Jakub Misiak, Martyna Kępczyk, Oliwia Kwaśniewska, Michał Urbaś, Miłosz Ojdana, Yehor Demianenko, Oliwia Czekaj, Aleksandra Kościołek, Dawid Kościołek, Kaja Surowiecka   +9 more
doaj   +1 more source

In vitro assessment of nutraceutical compounds and novel nutraceutical formulations in a liver-steatosis-based model [PDF]

, 2018
Antonietta Stellavato, Anna Virginia Adriana Pirozzi, Francesca de Novellis, Ilaria Scognamiglio, Valentina Vassallo, Andrea Maria Giori, Mario De Rosa, Chiara Schiraldi   +7 more
openalex   +1 more source

Quantitative Approaches to Accelerate MASH Drug Discovery and Development

Clinical Pharmacology &Therapeutics, EarlyView.
Metabolic dysfunction‐associated steatohepatitis (MASH) is a widespread liver condition that leads to cirrhosis, hepatic carcinoma, and increased mortality rates. In MASH, the diagnosis and accelerated approval of drugs are dependent on changes in histological endpoints; full approval requires lengthy outcomes trials.
Yasmeen Abouelhassan, Shailendra Tallapaka, Ramin Mehrani, Scott Q. Siler, Li Qin, Zeyuan Wang, Maria E. Trujillo   +6 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Noninvasive tests for nonalcoholic fatty liver disease in a multi‐ethnic population: The HELIUS study

Hepatology Communications, EarlyView., 2022
Abstract Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence and severity globally, prompting noninvasive testing, yet limited data exist on noninvasive liver tests (NITs) including transient elastography (TE) in ethnically diverse populations.
Anne‐Marieke van Dijk, Yasaman Vali, Anne Linde Mak, Henrike Galenkamp, Max Nieuwdorp, Bert‐Jan van den Born, Adriaan Georgius Holleboom   +6 more
wiley   +1 more source